The medication Trelegy is manufactured by GlaxoSmithKline (GSK) [1].
What is Trelegy used for?
Trelegy is a combination inhaler that contains three medications: fluticasone furoate, umeclidinium, and vilanterol. It is prescribed to patients with chronic obstructive pulmonary disease (COPD) for the long-term treatment of airflow obstruction and to reduce exacerbations. It is also indicated for the maintenance treatment of asthma in patients aged 18 and older [2].
How does Trelegy work?
Fluticasone furoate is an inhaled corticosteroid that reduces inflammation in the airways. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that helps to relax airway muscles. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that also helps to relax airway muscles. By combining these three active ingredients, Trelegy provides a triple therapy to manage COPD and asthma symptoms [2].
When did Trelegy become available?
Trelegy Ellipta was first approved by the U.S. Food and Drug Administration (FDA) in September 2017 for COPD patients [3]. Its approval for asthma patients followed in October 2020 [4].
Are there any alternatives to Trelegy?
Other combination inhalers are available for COPD and asthma management. These may include dual therapies with two active ingredients or other triple therapies from different manufacturers. Patients should consult their healthcare provider to determine the most suitable treatment option based on their individual needs and medical history [5].
What are the potential side effects of Trelegy?
Common side effects of Trelegy can include upper respiratory tract infection, pneumonia, bronchitis, headache, and back pain. Serious side effects may include paradoxical bronchospasm, pneumonia, hypersensitivity reactions, and effects related to the corticosteroid component, such as increased risk of bone fractures or ocular changes [2].
What is the patent status of Trelegy?
The patent landscape for pharmaceuticals like Trelegy is complex. Patents protect the active ingredients, formulations, and methods of use. Information on specific patents and their expiration dates can be found through resources like DrugPatentWatch.com, which tracks patent and exclusivity information for drugs [6].
---
Sources:
[1] https://www.gsksource.com/
[2] https://www.trelegy.com/
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-databases
[4] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-databases
[5] https://www.drugs.com/medical- Erounters/trelegy/
[6] https://drugpatentwatch.com/